Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
16 February 2018Website:
http://aadibio.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 17:54:05 GMTDividend
Analysts recommendations
Institutional Ownership
AADI Latest News
nab-Sirolimus demonstrated significantly greater intratumoral drug concentration, stronger inhibition of mTOR targets and greater antitumor activity compared to IV and oral mTOR inhibitors in a xenograft model Data support further clinical exploration of nab-sirolimus as a single agent or in combination LOS ANGELES , May 23, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced new nonclinical data demonstrating the significantly higher intratumoral drug concentration, stronger inhibition of mTOR targets and greater antitumor activity of nab-sirolimus compared to intravenous and oral mTOR inhibitors in a xenograft model. These data will be available as an abstract and published in the Journal of Clinical Oncology supplement to coincide with the American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 – June 4, 2024.
Aadi Bioscience, Inc. (NASDAQ: AADI) will be hosting a conference call and live webcast on May 8, 2024 at 8:30 am EDT to report their first quarter 2024 financial results and share recent corporate updates. Participants can join the webcast on the "Investors & News" page of the Aadi Bioscience website at aadibio.com.
Here is how Aadi Bioscience, Inc. (AADI) and Amplifon S.p.A. (AMFPF) have performed compared to their sector so far this year.
Here is how Aadi Bioscience, Inc. (AADI) and Amplifon S.p.A. (AMFPF) have performed compared to their sector so far this year.
Aadi Bioscience, Inc. (AADI) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.52 per share a year ago.
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Aadi Bioscience (NASDAQ: AADI ) stock is falling on Friday following the release of interim clinical trial data from its PRECISION1 study. This clinical trial covers the use of nab-sirolimus as a treatment for patients with TSC1 or TSC2 inactivating alterations.
Aadi Bioscience, Inc. (NASDAQ:AADI ) Q3 2023 Earnings Conference Call November 8, 2023 8:30 AM ET Company Participants Marcy Graham - Senior Vice President, Investor Relations and Corporate Communications Scott Giacobello - CFO Dave Lennon - President and CEO Loretta Itri - Chief Medical Officer Conference Call Participants Boris Peaker - Cowen Joe Catanzaro - Piper Sandler Roger Song - Jefferies Ahu Demir - Ladenburg Thalmann Operator Good day, and thank you for standing by. Welcome to the Aadi Bioscience Third Quarter 2023 Earnings Conference Call.
Aadi Bioscience, Inc. (AADI) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.73 per share a year ago.
Today, we take our first look at a small cap oncology name called Aadi Bioscience, Inc. The firm's main asset is a product called FYARRO which is approved for one rare indication and is being evaluated for additional tumor types. An investment analysis follows in the paragraphs below.
What type of business is Aadi Bioscience?
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
What sector is Aadi Bioscience in?
Aadi Bioscience is in the Healthcare sector
What industry is Aadi Bioscience in?
Aadi Bioscience is in the Biotechnology industry
What country is Aadi Bioscience from?
Aadi Bioscience is headquartered in United States
When did Aadi Bioscience go public?
Aadi Bioscience initial public offering (IPO) was on 16 February 2018
What is Aadi Bioscience website?
https://aadibio.com
Is Aadi Bioscience in the S&P 500?
No, Aadi Bioscience is not included in the S&P 500 index
Is Aadi Bioscience in the NASDAQ 100?
No, Aadi Bioscience is not included in the NASDAQ 100 index
Is Aadi Bioscience in the Dow Jones?
No, Aadi Bioscience is not included in the Dow Jones index
When does Aadi Bioscience report earnings?
The next expected earnings date for Aadi Bioscience is 09 August 2024